Literature DB >> 31491764

Predicting hearing outcomes before primary radiosurgery for vestibular schwannomas.

Stephen Johnson1,2, Hideyuki Kano1,2, Andrew Faramand1,2, Ajay Niranjan1,2, John C Flickinger3,2, L Dade Lunsford1,2.   

Abstract

OBJECTIVE: Optimizing outcomes in the management of patients with vestibular schwannomas (VSs) requires consideration of the patient's goals. Earlier recognition of VS by imaging has led to an evolution in management. Stereotactic radiosurgery (SRS) has emerged as a frequently used strategy designed to reduce management risks, obtain long-term tumor control, and preserve current neurological function. The authors analyzed features that impact hearing preservation rates in patients with serviceable hearing prior to SRS.
METHODS: The study included 307 patients who had serviceable hearing (Gardner-Robertson hearing scale [GR] grade 1 or 2, speech discrimination score ≥ 50%, pure tone average ≤ 50 dB) at the time of SRS. The authors evaluated parameters that included age, tumor volume, hearing status, disequilibrium, tinnitus, Koos class, sex, and tumor margin dose. The Pittsburgh Hearing Prediction Score (PHPS) was evaluated as a method to predict long-term hearing outcomes in these cases.
RESULTS: At a median of 7.6 years after SRS (range 1-23 years), tumor control was achieved in 95% of patients. The overall serviceable hearing preservation rate was 77.8% at 3 years, 68.8% at 5 years, and 51.8% at 10 years. The PHPS assigns a total of 5 points based on patient age (1 point if < 45 years, 2 points if 45-59 years, and 3 points if ≥ 60 years), tumor volume (0 points if < 1.2 cm3, 1 point if ≥ 1.2 cm3), and GR grade (0 points if grade 1 hearing, 1 point if grade 2 hearing) The serviceable hearing preservation rate was 92.3% at 10 years in patients whose score total was 1. In contrast, none of the patients whose PHPS was 5 maintained serviceable hearing at 10 years (p < 0.001).
CONCLUSIONS: SRS resulted in a high rate of long-term tumor control and cranial nerve preservation. The PHPS helped to predict long-term hearing preservation rates in patients who underwent SRS when they still had serviceable hearing. The best long-term hearing preservation rates were found in younger patients with smaller tumor volumes.

Entities:  

Keywords:  GR = Gardner-Robertson hearing scale; Gamma Knife; NF2 = neurofibromatosis type 2; PHPS = Pittsburgh Hearing Prediction Score; PTA = pure tone average; ROC = receiver operating characteristic; SDS = speech discrimination score; SRS = stereotactic radiosurgery; VS = vestibular schwannoma; acoustic neuroma; hearing; stereotactic radiosurgery; vestibular schwannoma

Year:  2019        PMID: 31491764     DOI: 10.3171/2019.5.JNS182765

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  4 in total

1.  Epidemiology of vestibular schwannoma in the United States, 2004-2016.

Authors:  Gino Cioffi; Debra N Yeboa; Michael Kelly; Nirav Patil; Nauman Manzoor; Katie Greppin; Kailey Takaoka; Kristin Waite; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  Neurooncol Adv       Date:  2020-10-10

2.  What determines quality of life in patients with vestibular schwannoma?

Authors:  Ineke M J Pruijn; Wietske Kievit; Mayke A Hentschel; Jef J S Mulder; Henricus P M Kunst
Journal:  Clin Otolaryngol       Date:  2020-12-28       Impact factor: 2.597

3.  An aberrant venous channel mimicking the perilabyrinthine cells in the petrous bone of a patient with vestibular schwannoma: illustrative case.

Authors:  Masato Ito; Yoshinori Higuchi; Kentaro Horiguchi; Shigeki Nakano; Shinichi Origuchi; Kyoko Aoyagi; Toru Serizawa; Iwao Yamakami; Yasuo Iwadate
Journal:  J Neurosurg Case Lessons       Date:  2021-11-01

Review 4.  Outcomes of stereotactic radiosurgery for large vestibular schwannomas: a systematic review and meta-analysis.

Authors:  Umberto Tosi; Miguel E Tusa Lavieri; Anjile An; Omri Maayan; Sergio W Guadix; Antonio P DeRosa; Paul J Christos; Susan Pannullo; Philip E Stieg; Andrew Brandmaier; Jonathan P S Knisely; Rohan Ramakrishna
Journal:  Neurooncol Pract       Date:  2021-02-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.